CLINICAL RESEARCH: ELECTROPHYSIOLOGY
Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation
Yukiko Nakano, MD*,*,
Shumpei Niida, PhD ,
Keigo Dote, MD ,
Sou Takenaka, MD*,
Hidekazu Hirao, MD*,
Fumiharu Miura, MD*,
Mari Ishida, MD*,
Tetsuji Shingu, MD*,
Taijiro Sueda, MD ,
Masao Yoshizumi, MD|| and
Kazuaki Chayama, MD*
* Department of Medicine and Molecular Science, Graduate School of Biomedical Science, Hiroshima University, Hiroshima, Japan
Department of Geriatric Research, National Institute for Longevity Science (NILS), Nagoya, Japan
Department of Cardiology, Hiroshima City Asa Hospital, Hiroshima, Japan
Department of Surgery, Hiroshima Graduate School of Medicine, Graduate School of Biomedical Science, Hiroshima University, Hiroshima, Japan
|| Department of Cardiovascular Physiology and Medicine, Graduate School of Biomedical Science, Hiroshima University, Hiroshima, Japan
Manuscript received July 2, 2003;
revised manuscript received July 28, 2003,
accepted August 5, 2003.
* Reprint requests and correspondence: Dr. Yukiko Nakano, Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
ynakano{at}xj8.so-net.ne.jp
OBJECTIVES: The purpose of this study was to determine the relationship between matrix metalloproteinases (MMPs)-1, -2, and -9, and tissue inhibitors of metalloproteinases (TIMP)-1 and the atrial structural remodeling during atrial fibrillation (AF).
BACKGROUND: Matrix metalloproteinases, a family of proteolytic enzymes and TIMPs, regulate the extracellular matrix turnover in cardiac tissue.
METHODS: Tissue samples were obtained from 25 patients without a history of AF (regular sinus rhythm [RSR]) and 13 patients with AF (paroxysmal AF: 6, chronic AF 7) undergoing cardiac operations. We performed a western blotting analysis of the MMP-1, -2, and -9, and quantitatively analyzed the expression of the MMP-9 and TIMP-1 by real time polymerase chain reaction and ELISA. The localization of the MMP-9 was investigated by in situ zymography and immunohistochemistry.
RESULTS: The active form of the MMP-9 was significantly increased in the AF group in comparison to that in the RSR group (p < 0.05), but there were no differences between the groups in the protein level of the latent form of the MMP-9 and active and latent forms of the MMP-1 and MMP-2. We also demonstrated that the expression of the MMP-9 was significantly more increased in the atria of the AF group than in that of the RSR group for both the messenger ribonucleic acid (mRNA) (AF: RSR; 1: 1.5) and protein levels (AF: RSR; 3.9 ± 1.3 : 1.5 ± 0.4 ng/mg atrium). The expression level of the MMP-9 was also higher in the PAF group than in the RSR group, however, the diameter of the left atrium was similar in both groups. The gelatinase activity and left atrium diameter were positively correlated (p < 0.05, R = 0.766). The relative expression of the mRNA for the monocyte chemoattractant protein-1 was higher in the AF group than in the RSR group. Immunohistochemical analysis revealed that the MMP-9 was distributed within the perivascular area and under the epicardium of the atria.
CONCLUSIONS: We clearly showed that the expression of the MMP-9 increased in fibrillating atrial tissue, which may have contributed to the atrial structural remodeling and atrial dilatation during AF.
|
Abbreviations and Acronyms
| | AF | = atrial fibrillation | | ADAM | = A Disintegrin And Metalloproteinase | | MCP-1 | = monocyte chemoattractant protein-1 | | MMPs | = matrix metalloproteinases | | PAF | = paroxysmal AF | | RSR | = regular sinus rhythm | | RT-PCR | = reverse transcription-polymerase chain reaction | | TIMPs | = tissue inhibitors of metalloproteinases |
|
This article has been cited by other articles:
|
|
|
|
 
M. Shimano, Y. Inden, Y. Tsuji, H. Kamiya, T. Uchikawa, R. Shibata, and T. Murohara
Circulating homocysteine levels in patients with radiofrequency catheter ablation for atrial fibrillation
Europace,
August 1, 2008;
10(8):
961 - 966.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Pan, C.-H. Wen, and C.-S. Lin
Interplay of angiotensin II and angiotensin(1-7) in the regulation of matrix metalloproteinases of human cardiocytes
Exp Physiol,
May 1, 2008;
93(5):
599 - 612.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nattel, B. Burstein, and D. Dobrev
Atrial Remodeling and Atrial Fibrillation: Mechanisms and Implications
Circ Arrhythm Electrophysiol,
April 1, 2008;
1(1):
62 - 73.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. W. Lee, T. H. Everett IV, D. Rahmutula, J. M. Guerra, E. Wilson, C. Ding, and J. E. Olgin
Pirfenidone Prevents the Development of a Vulnerable Substrate for Atrial Fibrillation in a Canine Model of Heart Failure
Circulation,
October 17, 2006;
114(16):
1703 - 1712.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Rucker-Martin, P. Milliez, S. Tan, X. Decrouy, M. Recouvreur, R. Vranckx, C. Delcayre, J.-F. Renaud, I. Dunia, D. Segretain, et al.
Chronic hemodynamic overload of the atria is an important factor for gap junction remodeling in human and rat hearts
Cardiovasc Res,
October 1, 2006;
72(1):
69 - 79.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rotter, P. Jais, M.-C. Vergnes, P. Nurden, Y. Takahashi, P. Sanders, T. Rostock, M. Hocini, F. Sacher, and M. Haissaguerre
Decline in C-Reactive Protein After Successful Ablation of Long-Lasting Persistent Atrial Fibrillation
J. Am. Coll. Cardiol.,
March 21, 2006;
47(6):
1231 - 1233.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. P. Beukema, A. Elvan, H. T. Sie, A. R. Ramdat Misier, and H. J.J. Wellens
Successful Radiofrequency Ablation in Patients With Previous Atrial Fibrillation Results in a Significant Decrease in Left Atrial Size
Circulation,
October 4, 2005;
112(14):
2089 - 2095.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Anne, R. Willems, T. Roskams, P. Sergeant, P. Herijgers, P. Holemans, H. Ector, and H. Heidbuchel
Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation
Cardiovasc Res,
September 1, 2005;
67(4):
655 - 666.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Barth, S. Merk, E. Arnoldi, L. Zwermann, P. Kloos, M. Gebauer, K. Steinmeyer, M. Bleich, S. Kaab, M. Hinterseer, et al.
Reprogramming of the Human Atrial Transcriptome in Permanent Atrial Fibrillation: Expression of a Ventricular-Like Genomic Signature
Circ. Res.,
May 13, 2005;
96(9):
1022 - 1029.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Porter, N. A. Turner, D. J. O'Regan, and S. G. Ball
Tumor necrosis factor {alpha} induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin
Cardiovasc Res,
December 1, 2004;
64(3):
507 - 515.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
